...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Open Journal of Ophthalmology >Micro-Invasive Glaucoma Surgery with the iStent inject: Impact on IOP and Medication Burden in a Real-World Setting
【24h】

Micro-Invasive Glaucoma Surgery with the iStent inject: Impact on IOP and Medication Burden in a Real-World Setting

机译：微创青光眼手术与不注射的术：对真实世界环境中的IOP和药物负担的影响

获取原文
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: The iStent inject is a Micro-Invasive Glaucoma Surgical (MIGS) device that has shown to reduce IOP and to be safe for glaucoma patients with fewer complications than regular surgery. Objective: To investigate, up to 15 - 20 months, the efficacy and safety of implantation of two second-generation trabecular microbypass stents in patients with or without prior glaucoma surgery. Methods: Fifty-seven eyes were implanted with the iStent inject. The population was comprised of eyes with primary open-angle glaucoma (n = 51), pseudoexfoliation glaucoma (n = 5) and ocular hypertension (n = 1). Major outcome parameters included IOP, medication needs and corrected distance visual acuity (CDVA). Follow-up time points were one day, 2 - 4 months, 9 - 14 months and 15 - 20 months. Results: The main reason to perform MIGS was IOP reduction in 68.4%, reduced number of medications due to drug intolerance in 24.6% and reduced medication due to compliance issues in 7.0% of the eyes. IOP decreased by 22.47%, from 19.40 ± 3.83 mmHg preoperatively (preop) to 15.04 ± 1.67 mmHg at 15-20 months postoperatively. IOP reduction was achieved at all follow-up time points (p < 0.001). A decrease in the number of medications was achieved in 32.1% of the patients after 15 - 20 months. Conclusions: Insertion of the iStent inject in patients with or without prior glaucoma surgery shows effective and sustained improvements in IOP with no safety concerns.
机译：背景：本发明的注射是一种微创青光眼外科手术（MIGS）装置，其显示用于减少IOP并对比常规手术的并发症较少的青光眼患者安全。目的：探讨，高达15至20个月，植入两种第二代小梁微玻璃支架的疗效和安全性，患者患者或没有现有的青光眼手术。方法：植入五十七只眼睛的注射。人口由具有初级开口角膜（n = 51）的眼睛组成，伪挑解青光眼（n = 5）和眼高血压（n = 1）组成。主要结果参数包括IOP，药物需求和矫正距离视力（CDVA）。随访时间点是一天，2 - 4个月，9 - 14个月和15 - 20个月。结果：表演MIGS的主要原因是IOP降低68.4％，由于药物不耐受24.6％，药物的药物数量减少，并且由于7.0％的眼睛的合规问题而减少药物。 IOP从19.40±3.83mmHg术前（拍摄）从19.40±3.83mmHg降低了22.47％。在所有后续时间点（P <0.001）实现IOP还原。在15-20个月后，在32.1％的患者中达到了药物数量的减少。结论：在患有或没有先前的青光眼手术的患者中插入不含安全性的有效和持续改善，没有安全顾虑。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号